Insmed reported $606.26M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
DBV Technologies USD 64.8M 16.9M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Novartis USD 13.19B 3.9B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026